EGFR and neoplasm: For example, a study of intratumor heterogeneity of EGFR mutations in non-small-cell lung cancer found that tumors that contain both mutation-positive and mutation-negative tumor cells are less responsive to gefitinib than tumors that do not display such heterogeneity [5].